Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial

• From January 1, 1983, through December 31, 1992, a total of 4610 patients entered a randomized trial that compared mortality among patients receiving 2 years of adjuvant tamoxifen therapy with that in patients receiving 5 years of adjuvant tamoxifen therapy, 4175 of whom were recurrence free after 2 years of tamoxifen therapy. Among the 2046 patients randomly assigned to the 5-year group all-cause mortality, breast cancer-specific mortality, and the incidence of contralateral breast cancer were reduced, compared with those among 2129 patients randomized in the 2-year group, but the incidence of endometrial cancer was increased. In addition, mortality from coronary heart disease was statistically significantly reduced in the 5-year group, compared with that in the 2-year group (hazard ratio = 0.67, 95% confidence interval = 0.47 to 0.94; P = .022 [two-sided Wald test]). Ten years after surgery, 2.1% of the patients in the 5-year group and 3.5% of those in the 2-year group had died from coronary heart disease. No statistically significant increases in mortality from other heart diseases, cerebrovascular diseases, or other vascular diseases were observed.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Aged

Antineoplastic Agents

Hormonal/*administration & dosage

Breast Neoplasms/*drug therapy/prevention & control

Chemotherapy

Adjuvant

Coronary Disease/*mortality

Drug Administration Schedule

Estrogen Receptor Modulators/*administration & dosage

Female

Humans

Incidence

Middle Aged

Mortality/trends

Odds Ratio

Postmenopause

Proportional Hazards Models

Registries

Sweden/epidemiology

Tamoxifen/*administration & dosage

Time Factors

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)